IceCure Medical Ltd (NASDAQ:ICCM) Q3 2022 Results Conference Call December 2, 2022 8:00 AM ET
Company Participants
Eyal Shamir - Chief Executive Officer
Ronen Tsimerman - Chief Financial Officer
Hania Bednarski - Oncoplastic Breast Surgeon and Cryoablation Specialist
Conference Call Participants
Ben Haynor - Alliance Global Partners
Anthony Vendetti - Maxim Group
Kemp Dolliver - Brookline Capital Markets
Operator
Welcome to IceCure’s Conference Call on the Financial Results for the Nine Months Ended September 30, 2022, and update on recent operational highlights. Management will provide an overview of IceCure's financial results as well as clinical, commercial and operational highlights.
Participating on the call today are IceCure’s CEO, Eyal Shamir; and CFO, Ronen Tsimerman. They are joined by Dr. Hania Bednarski, Oncoplastic Breast Surgeon and Cryoablation Specialist at Serenity Surgery & Wellness in Myrtle Beach, South Carolina. Currently, all participants are in a listen only mode. Following the presentation, IceCure's management and Dr. Bednarski will be available for the question-and-answer session.
Before we begin, I will now take a moment to read the statement about forward-looking statements. This call and the question-and-answer session that follows it contains forward-looking statements within the meaning of the Safe Harbor provisions of the Private Securities Litigation Reform Act of 1995 and other federal securities laws. Words such as expects, anticipates, intends, plans, believes, seeks, estimates, and similar expressions or variations of such words are intended to identify forward-looking statements. For example, we are using forward-looking statement in this presentation when we discusses pursuit of regulatory approvals in various jurisdictions, strategic plans, commercial growth, expansion of clinical applications release of results from our clinical trials, potential market adoption and future sales of IceCure's minimally-invasive cryoablation technology, advancing regulatory and commercial strategies and expected quarter-over-quarter revenue variations and other key business and operational highlights for future periods. Because such statements deal with future events and are based on IceCure’s current expectations, they are subject to various risks and uncertainties and actual results, performance, or achievements of IceCure could differ materially from those described in or implied by the statements in this presentation.
The forward-looking statements contained or implied in this presentation are subject to other risks and uncertainties, many of which are beyond the control of the company, including those set forth in the Risk Factors section of the company’s Annual Report on Form 20-F for the year ended December 31, 2021 filed with the SEC on April 1, 2022, which is available on the SEC’s website, www.sec.gov. The company undertakes no obligation to update these statements or revisions or changes after the date of this release, except as required by law.